John Meletis

Dr. John Meletis


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
PDPanagiotis Theodorou Diamantopoulos
Panagiotis Theodorou Diamantopoulos
MMMaria Michael
Maria Michael
OBOlga Benopoulou
Olga Benopoulou
EBEfthymia Bazanis
Efthymia Bazanis
GTGeorge Tzeletas
George Tzeletas
NVNora-Athina Viniou
Nora-Athina Viniou
Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative. This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo.

1 January 2001 in The Hematology Journal
Verified
Journal Article
Closed access
JMJohn Meletis
John Meletis
Evangelos TerposEvangelos Terpos
Evangelos Terpos
MSMichalis Samarkos
Michalis Samarkos
CMChristos Meletis
Christos Meletis
EAEffie Apostolidou
Effie Apostolidou
DLDimitris Loukopoulos
Dimitris Loukopoulos

1 January 2011 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
MMMarina Mantzourani
Marina Mantzourani
HGHelen Gogas
Helen Gogas
AKAikaterini Katsandris
Aikaterini Katsandris
JMJohn Meletis
John Meletis
Trastuzumab is a humanized, monoclonal antibody that interferes with the HER2/neu receptor and binds selectively to the HERB2 protein which causes uncontrolled proliferation of malignant breast cells. We report a case of severe thrombocytopenia related to trastuzumab administration. Three days after the first dose of single-agent trastuzumab, the patient was admitted to the hospital with nose bleeding, petechiae and platelet counts of 5×109/L. The patient showed a self-limiting trastuzumab-related thrombocytopenia. Among the reported cases of trastuzumab-induced severe thrombocytopenia, this patient is the only one who did not interrupt trastuzumab treatment. It is possible that our patient showed progressive reduction of immune-mediated thrombocytopenia caused by trastuzumab administration.

27 July 2010 in Anemia
Verified
Journal Article
Open access
PDF file
JMJohn Meletis
John Meletis
KKKostas Konstantopoulos
Kostas Konstantopoulos
All ancient nations hinged their beliefs about hema (blood) on their religious dogmas as related to mythology or the origins of religion. The Hellenes (Greeks) especially have always known hema as the well-known red fluid of the human body. Greek scientific considerations about blood date from Homeric times. The ancient Greeks considered hema as synonymous with life. In Greek myths and historical works, one finds the first references to the uninterrupted vascular circulation of blood, the differences between venous and arterial blood, and the bone marrow as the site of blood production. The Greeks also speculated about mechanisms of blood coagulation and the use of blood transfusion to save life.

1 January 2002 in Hematology
Verified
Journal Article
Closed access
JMJohn Meletis
John Meletis
Evangelos TerposEvangelos Terpos
Evangelos Terpos
MSMichalis Samarkos
Michalis Samarkos
CMChristos Meletis
Christos Meletis
EAEffie Apostolidou
Effie Apostolidou
KKKonstantinos Konstantopoulos
Konstantinos Konstantopoulos
CD55 and CD59 are complement regulatory proteins that are linked to the cell membrane via a glycosyl-phosphatidylinositol anchor. They are reduced mainly in paroxysmal nocturnal hemoglobinuria (PNH) and in other hematological disorders. However, there are very few reports in the literature concerning their expression in patients with acute leukemias (AL). We studied the CD55 and CD59 expression in 88 newly diagnosed patients with AL [65 with acute non-lymphoblastic leukemia (ANLL) and 23 with acute lymphoblastic leukemia (ALL)] using the sephacryl gel test, the Ham and sucrose lysis tests and we compared the results with patients' clinical data and disease course. Eight patients with PNH were also studied as controls. Red cell populations deficient in both CD55 and CD59 were detected in 23% of ANLL patients (especially of M0, M2 and M6 FAB subtypes), 13% of ALL and in all PNH patients. CD55-deficient erythrocytes were found in 6 ANLL patients while the expression of CD59 was decreased in only 3 patients with ANLL. No ALL patient had an isolated deficiency of these antigens. There was no correlation between the existence of CD55 and/or CD59 deficiency and the percentage of bone marrow infiltration, karyotype or response to treatment. However no patient with M3, M5, M7 subtype of ANLL and mature B- or T-cell ALL showed a reduced expression of both antigens. The deficient populations showed no alteration after chemotherapy treatment or during disease course. This study provides evidence about the lower expression of CD55 and CD59 in some AL patients and the correlation with their clinical data. The possible mechanisms and the significance of this phenotype are discussed.

1 January 2014 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
JMJohn Meletis
John Meletis
JAJohn V. Asimakopoulos
John V. Asimakopoulos
ETEvangelos Terpos
Evangelos Terpos
LPLoula Papageorgiou
Loula Papageorgiou
OKOlga Kampouropoulou
Olga Kampouropoulou
Theodoros VassilakopoulosTheodoros Vassilakopoulos
Theodoros Vassilakopoulos
Background:Complement has the potential to provoke severe impairment to host tissues, as shown in autoimmune diseases where complement activation has been associated with diminished CD55 and/or CD59 expression on peripheral blood cell membranes. The ...